Two Biotech Companies Report 2025 Financial Results and Pipeline Progress

Edgewise Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for rare neuromuscular and cardiac diseases, reported a net loss of $167.8 million for the year, reflecting an increase from the previous year's net loss of $133.8 million, primarily due to higher research and development expenses. IDEAYA Biosciences, Inc., a precision medicine oncology firm, reported a net loss of $(113.7) million, improved by $160.8 million or 59% compared to the previous year.

Edgewise reported total operating expenses of $191.4 million, up from $158.8 million in the prior year, driven by increased research and development activities and general and administrative expenses. Research and development expenses reached $151.4 million, an increase from $127.0 million in the previous year, largely due to the advancement of clinical programs and increased personnel-related costs. General and administrative expenses totaled $40.0 million, up from $31.9 million in the previous year, primarily due to increased personnel-related costs and professional fees. Interest income was $23.6 million, a slight decrease from $25.0 million in the previous year, attributed to lower average treasury yields despite higher average securities balances.

IDEAYA reported collaboration revenue of $218.7 million, increased by $211.7 million or 3,024% compared to the previous year, primarily due to the Servier License Agreement. Loss from operations was $(159.3) million, improved by $167.7 million or 51% compared to the previous year. Interest income and other income, net, totaled $45.6 million, decreased by $6.9 million or 13% compared to the previous year.

Edgewise is advancing sevasemten, an orally administered myosin inhibitor, in late-stage clinical trials for Duchenne and Becker muscular dystrophies. The FDA has granted Fast Track and Orphan Drug Designations for these indications. Positive results from the ARCH and CANYON trials in Becker muscular dystrophy show stabilization of function and reduction in muscle damage biomarkers with sevasemten treatment. The DUNE study demonstrated significant reductions in muscle damage biomarkers post-exercise in Becker patients treated with sevasemten. The MESA trial continues to show sustained disease stabilization in Becker patients previously enrolled in ARCH and CANYON trials. The LYNX and FOX trials are ongoing in Duchenne, with LYNX showing promising functional improvements and FOX assessing sevasemten in gene therapy-treated Duchenne patients.

EDG-7500, a cardiac sarcomere modulator, is in a Phase 2 trial for hypertrophic cardiomyopathy (HCM). A second modulator, EDG-15400, is in Phase 1 trials targeting heart failure with preserved ejection fraction (HFpEF). The EDG-003 discovery program is exploring candidates for cardiometabolic diseases, indicating potential pipeline expansion into other muscle diseases.

IDEAYA's clinical pipeline includes nine potential first-in-class product candidates across four focus areas: Darovasertib for Uveal Melanoma, ADC and DNA Damage Response Combinations, MTAP Pathway, and Next Generation Therapies. Darovasertib, the most advanced clinical program, targets Uveal Melanoma, a rare ocular cancer. Multiple trials are being conducted in metastatic and pre-metastatic settings, with a Phase 2/3 trial expected to report data in Q1 2026. Darovasertib has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA.

IDE849 and IDE034 are key candidates exploring combinations of topoisomerase I inhibitor-based ADCs and DDR pathway inhibitors, with IDE849 showing promising Phase 1 data in SCLC and NEC. IDE397 is a MAT2A inhibitor being evaluated in combination with Trodelvy for MTAP-deleted urothelial and non-small cell lung cancers. Initial data from a Phase 1/2 trial in UC patients was presented in 2025. IDEAYA is developing next-generation therapies targeting tumor driver pathways, including IDE574, a dual KAT6/7 inhibitor, and IDE275, a WRN helicase inhibitor, with Phase 1 trials planned for 2026.

Edgewise has financed its operations primarily through private placements of convertible preferred stock and public offerings of common stock, raising a total of $793.7 million as of December 31, 2025. In 2025, Edgewise completed an underwritten registered direct offering, raising $200 million in gross proceeds. The company also has an 'at the market offering' program with Leerink Partners LLC, allowing for the sale of up to $175 million in common stock. As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $530.1 million.

IDEAYA primarily funded operations through the sale of common stock and milestone payments from strategic partners. In 2025, the company sold shares for net proceeds of $25 million under the January 2024 Sales Agreement. IDEAYA completed a public follow-on offering in July 2024, raising approximately $283.8 million in net proceeds. As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $1.05 billion.

IDEAYA established collaborations with Pfizer, Gilead, Servier, and others to support clinical development and commercialization efforts. A notable agreement with Servier grants them rights to darovasertib outside the U.S. The company also has a collaboration with Hengrui Pharma for the development of IDE849.

Edgewise holds a robust patent portfolio covering compositions of matter and methods of treatment for its key drug candidates, with patents expected to expire between 2039 and 2044. The company relies on third-party CDMOs for manufacturing and plans to identify additional manufacturers for regulatory approval processes. IDEAYA relies on third-party manufacturers for the production of its product candidates and biomarker diagnostics, with no plans to establish its own manufacturing facilities.